¼¼°èÀÇ RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð Á¶»ç : ¾à¹° À¯Çüº°, Åõ¿© °æ·Îº°, ȯÀÚ À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
»óǰÄÚµå : 1534229
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : ¹ßÇ࿹Á¤
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages

¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2023³â ¾à 58¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È 12.82% ÀÌ»óÀÇ °Ç°­ÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦´Â RS ¹ÙÀÌ·¯½º(RSV)¿¡ ÀÇÇÑ °¨¿°À» ¿¹¹æ, °ü¸® ¹× Ä¡·áÇϱâ À§ÇÑ ´Ù¾çÇÑ ÀÇ·áÀû °³ÀÔÀ» Æ÷ÇÔÇÕ´Ï´Ù. RSV´Â ÀϹÝÀûÀ¸·Î °Ç°­ÇÑ »ç¶÷¿¡°Ô´Â °¡º­¿î °¨±â¿Í °°Àº Áõ»óÀ» À¯¹ßÇÏÁö¸¸, ¿µÀ¯¾Æ, ³ëÀÎ, ¸é¿ª·ÂÀÌ ¾àÇϰųª ±âÀúÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷ µî Ãë¾àÇÑ Áý´Ü¿¡¼­´Â ½É°¢ÇÑ È£Èí±â ÁúȯÀ¸·Î ¹ßÀüÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, Drug Discovery ±â¼úÀÇ ¹ßÀü µîÀ» ¹è°æÀ¸·Î ½ÃÀåÀº °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ºÐ¾ß´Â ¾ö°ÝÇÑ ±ÔÁ¦¿Í °³¹ßµµ»ó±¹ÀÇ Á¦ÇÑµÈ ÀÇ·á ÀÎÇÁ¶ó µî Å« µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.

RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº ¸¸¼º È£Èí±â ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è ÇコÄɾî ÁöÃâÀÇ Áõ°¡·Î ÀÎÇØ ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Drug Discovery ±â¼úÀÇ ¹ßÀüµµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ RSV Ä¡·áÁ¦ÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀǾàǰ ½ÂÀÎ ÀýÂ÷¸¦ Áö¿¬½ÃŰ´Â ±ÔÁ¦ À庮°ú ¸¹Àº ½ÅÈï±¹ÀÇ Á¦ÇÑµÈ ÀÇ·á ÀÎÇÁ¶ó°¡ ÀÌ·¯ÇÑ Ä¡·áÁ¦¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±ÙÀ» ¹æÇØÇϰí ÀÖ¾î ½ÃÀå È®´ë°¡ Á¦Çѵǰí ÀÖ½À´Ï´Ù.

RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. 2023³â ºÏ¹Ì°¡ RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ½ÃÀåÀ» Áö¹èÇßÀ¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â À¯¸®ÇÑ »óȯ Á¤Ã¥°ú Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡, RSV¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼±À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à

Á¦2Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤

Á¦3Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦4Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¾à¹° À¯Çüº°, 2022-2032³â

Á¦6Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Åõ¿© °æ·Îº°, 2022-2032³â

Á¦7Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ȯÀÚ À¯Çüº°, 2022-2032³â

Á¦8Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°, 2022-2032³â

Á¦9Àå RS ¹ÙÀÌ·¯½º Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

Á¦10Àå °æÀï Á¤º¸

Á¦11Àå Á¶»ç °úÁ¤

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast period 2024-2032. Respiratory syncytial virus therapeutics encompasses a variety of medical interventions aimed at preventing, managing, and treating infections caused by the respiratory syncytial virus (RSV). While RSV generally induces mild, cold-like symptoms in healthy individuals, it can escalate to severe respiratory illnesses in vulnerable populations such as infants, older adults, and those with compromised immune systems or underlying health conditions. The market is experiencing robust growth driven by the increasing prevalence of chronic respiratory conditions, rising healthcare expenditures, and technological advancements in drug discovery. However, the sector also faces significant challenges, including stringent regulatory hurdles and limited healthcare infrastructure in developing regions.

The Global Respiratory Syncytial Virus Therapeutics Market is driven by rise in chronic respiratory conditions prompting substantial investment in research and development. Additionally, higher healthcare expenditure globally has facilitated greater access to advanced therapies, boosting market growth. Technological advancements in drug discovery have also played a crucial role, leading to the development of innovative and more effective RSV therapies. However, the market's expansion is tempered by regulatory hurdles that can delay drug approval processes and the limited healthcare infrastructure in many developing countries, which hampers widespread access to these treatments.

The key regions considered for the Global Respiratory Syncytial Virus Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the respiratory syncytial virus therapeutics market in terms of revenue in 2023, a trend that is expected to continue due to favorable reimbursement policies and a well-established healthcare infrastructure. Furthermore, the Asia Pacific region is poised to exhibit the fastest growth over the forecast period, driven by increasing healthcare expenditure, rising awareness about RSV, and improving healthcare infrastructure.

Major market players included in this report are:

The detailed segments and sub-segment of the market are explained below:

By Drug Type:

By Route of Administration:

By Patient Type:

By Distribution Channel:

By Region:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1. Global Respiratory Syncytial Virus Therapeutics Market Executive Summary

Chapter 2. Global Respiratory Syncytial Virus Therapeutics Market Definition and Research Assumptions

Chapter 3. Global Respiratory Syncytial Virus Therapeutics Market Dynamics

Chapter 4. Global Respiratory Syncytial Virus Therapeutics Market Industry Analysis

Chapter 5. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Drug Type 2022-2032

Chapter 6. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Route of Administration 2022-2032

Chapter 7. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Patient Type 2022-2032

Chapter 8. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Distribution Channel 2022-2032

Chapter 9. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Region 2022-2032

Chapter 10. Competitive Intelligence

Chapter 11. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â